Moderna (MRNA) Stock Forecast & Price Target

$59.17 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$61.08 +1.92 (+3.24%)

As of 07:42 AM Eastern

Compare

Moderna - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Reduce

Based on 17 Analyst Ratings

Sell
5

Hold
9

Buy
3

Based on 17 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 17 analysts, 5 have given a sell rating, 9 have given a hold rating, and 3 have given a buy rating for MRNA.

Consensus Price Target

$42.13
-28.79% Downside

According to the 17 analysts' twelve-month price targets for Moderna, the average price target is $42.13. The highest price target for MRNA is $77.00, while the lowest price target for MRNA is $18.00. The average price target represents a forecasted downside of -28.79% from the current price of $59.17.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MRNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Moderna and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRNA Analyst Ratings Over Time

Type	Current Forecast 8/10/25 to 8/10/26	1 Month Ago 7/11/25 to 7/11/26	3 Months Ago 5/12/25 to 5/12/26	1 Year Ago 8/10/24 to 8/10/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	9 Hold rating(s)	11 Hold rating(s)	12 Hold rating(s)	15 Hold rating(s)
Sell	5 Sell rating(s)	5 Sell rating(s)	5 Sell rating(s)	4 Sell rating(s)
Consensus Price Target	$42.13	$38.27	$35.73	$43.59
Forecasted Upside	-28.79% Downside	-43.95% Downside	-32.92% Downside	66.88% Upside
Consensus Rating	Reduce	Reduce	Reduce	Reduce

MRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Moderna Stock vs. The Competition

Type	Moderna	Healthcare Companies	Broader Market
Consensus Rating Score	1.88	2.30	2.53
Consensus Rating	Reduce	Hold	Moderate Buy
Predicted Upside	-28.79% Downside	862.06% Upside	11.64% Upside
News Sentiment Rating	Neutral News See Recent MRNA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/3/2026	UBS Group 4 of 5 stars	Eliana Merle 4 of 5 stars	Reiterated Rating	Overweight
8/3/2026	Piper Sandler 2 of 5 stars	Edward Tenthoff 4 of 5 stars	Reiterated Rating	Overweight
8/3/2026	Citigroup 4 of 5 stars	Geoff Meacham 5 of 5 stars	Boost Target	Neutral	$41.00 ➝ $60.00	+9.45%
7/21/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$49.00 ➝ $67.00	+12.62%
7/20/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Underperform	$25.00	-59.56%
7/8/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$33.00 ➝ $39.00	-48.90%
7/7/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Perform	$38.00 ➝ $45.00	-44.99%
7/7/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dimple Gosai Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Underperform	$34.00 ➝ $38.00	-52.16%
6/18/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
6/12/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell (D-)
This tiny piece of glass could be bigger than GPUs (Ad) Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capital - the firm behind Anthropic and OpenAI - calls it a 'holy grail.' It's smaller than a fingertip and made of glass. Wall Street insider Jason Bodner - who called Nvidia at $4.50 - believes this 'light-speed' device could be bigger for AI than GPUs and is about to launch a new wave of winners. He's sharing his number one stock pick tied to it at no cost. Click here to get Jason Bodner's top pick for free
4/2/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$25.00 ➝ $48.00	-1.74%
2/17/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cory Kasimov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$35.00	-18.79%
2/17/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform	$45.00	+6.56%
1/30/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mani Foroohar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Underperform
1/29/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
1/12/2026	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Market Perform ➝ Buy
11/17/2025	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$28.00	+13.04%
10/23/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Underweight	$26.00 ➝ $25.00	-4.49%
10/20/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
7/13/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Equal Weight
6/2/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform
12/18/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jasper Hellweg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
11/18/2024	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$58.00	+57.39%
9/13/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:30 AM ET.

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, August 7, 2026. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

Moderna
Bull Case

Here are some ways that investors could benefit from investing in Moderna, Inc.:

Moderna, Inc. reported a second-quarter earnings per share of -$1.97, which was better than the consensus estimate, indicating improved financial performance.
The company achieved revenue of approximately $145 million for the quarter, surpassing expectations and showing a year-over-year growth of about 2.1%.
Moderna, Inc. has plans for up to 10% revenue growth in 2026, which could enhance future profitability and attract investors looking for growth opportunities.
Analysts have recently raised their target prices for Moderna, Inc., with some estimates reaching as high as $77.00, suggesting potential upside for the stock.
The current stock price is around $40.00, which may be considered attractive for investors looking to enter at a lower valuation compared to its potential growth trajectory.

Moderna
Bear Case

Investors should be bearish about investing in Moderna, Inc. for these reasons:

Moderna, Inc. has a negative return on equity of 28.30%, indicating that the company is not generating profit from its equity, which could be a red flag for investors.
The company has faced challenges with COVID-19 vaccine sales, which were weaker than expected, raising concerns about declining demand for its core product.
Moderna's mRNA-1403 norovirus vaccine did not meet the statistical criteria for early success in a Phase 3 interim analysis, which could delay potential revenue from this product.
Despite recent revenue growth, the company has a negative net margin of 141.43%, suggesting that it is currently spending more than it earns, which could impact long-term sustainability.
There are mixed ratings from analysts, with a consensus rating of "Reduce," indicating that some experts are cautious about the stock's future performance.

MRNA Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $42.13, with a high forecast of $77.00 and a low forecast of $18.00.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 5 sell ratings, 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" MRNA shares.

According to analysts, Moderna's stock has a predicted downside of -28.79% based on their 12-month stock forecasts.

Moderna has been rated by research analysts at Bank of America, Citigroup, Jefferies Financial Group, Morgan Stanley, Piper Sandler, Royal Bank Of Canada, The Goldman Sachs Group, UBS Group, Weiss Ratings, and Wolfe Research in the past 90 days.

Analysts like Moderna less than other "healthcare" companies. The consensus rating for Moderna is Reduce while the average consensus rating for "healthcare" companies is Hold. Learn more on how MRNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Moderna Recommendations

This page (NASDAQ:MRNA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moderna (MRNA) Stock Forecast & Price Target

Moderna - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

MRNA Analyst Ratings Over Time

MRNA Analyst Recommendations By Month

MRNA Price Targets by Month

Moderna Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

Moderna
Bull Case

Moderna
Bear Case

MRNA Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Moderna Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Moderna (MRNA) Stock Forecast & Price Target

Moderna - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

MRNA Analyst Ratings Over Time

MRNA Analyst Recommendations By Month

MRNA Price Targets by Month

Moderna Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

Moderna Bull Case

Moderna Bear Case

MRNA Forecast - Frequently Asked Questions

What is Moderna's forecast for 2026?

Should I buy or sell Moderna stock right now?

Does Moderna's stock price have much downside?

What analysts cover Moderna?

Do Wall Street analysts like Moderna more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Moderna Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Moderna
Bull Case

Moderna
Bear Case